Anixa Biosciences begins treating fifth patient in ovarian cancer CAR-T trial

Anixa Biosciences announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center. Anixa’s first-in-human trial is enrolling female adult patients with recurrent/progressing ovarian cancer who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. . The study will identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor, found only on ovarian cells. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.